Physician profile
Deepak Mital
NPI 1720024219
$56,139.11
in general payments reported to CMS, 2019-2025
15 companies · $50.03 in 2025
The $50.03 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $8,620 · 2021: $15K · 2022: $1,453 · 2023: $106 · 2024: $244 · 2025: $50.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $54,876.40 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $195.78 | 2019-2024 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $187.95 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $130.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.08 | 2023-2024 | Livtencity |
| One Lambda, INC. | $119.17 | 2024 | |
| Abbvie INC. | $96.83 | 2020 | |
| Horizon Therapeutics Plc | $85.18 | 2021 | |
| Mallinckrodt Hospital Products INC. | $81.47 | 2024-2025 | Acthar |
| Genzyme Corporation | $77.20 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.51 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.05 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.98 | 2019 | |
| Kci USA, INC. | $15.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Mital listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.